title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Cost analysis | fracture, numbness, loss of reduction, pain, carpal tunnel syndrome | REGRESSION, PRESSURE SORE, CARPAL TUNNEL SYNDROME | The costs of treatment consisted of additional visits to the hospital, imaging and other examinations, physical therapy, and operative treatment. The mean overall cost of treatment per patient in the VFUDC group was €1 307 and €717 in the FC group. Thus, the costs per patient of VFUDC were €590 (82%) higher than the co... | PMC10079055 |
Discussion | fracture, fractures, Colles’ fractures, pain | DISEASE, SECONDARY | In this randomized, controlled, multicenter study, we found a small, imprecise but consistent, difference between groups in all primary and secondary functional results (PRWE, 15D QD, and VAS) favoring FC. The primary outcome, PRWE at 24 months, showed a difference of 5.37 points. However, this did not reach the predet... | PMC10079055 |
Strengths and limitations | COMPLICATIONS | In this study, we enrolled 105 patients. The drop-out rate at 12 months was 18% (19) and 23% (24) at 24 months. This was a higher rate than we expected, and the number of patients in the FC group was therefore lower than expected in the power analysis. However, the drop-out rate did not exceed 30% for long-term follow-... | PMC10079055 | |
Conclusions | fracture, Colles’ type of DRFs, Colles’ type DRF | We found a slight, but consistent difference in functional results between the VFUDC and FC groups. Our results suggest that FC produces non-inferior results compared to VFUDC in the treatment of Colles’ type of DRFs at 2 years with fewer problems and unnecessary healthcare provider visits, and less treatment-related b... | PMC10079055 | |
Supporting information | PMC10079055 | |||
CONSORT 2010 checklist of information to include when reporting a randomised trial. | (DOC)Click here for additional data file. | PMC10079055 | ||
Description of changes to the published protocol. | (DOCX)Click here for additional data file. | PMC10079055 | ||
Inclusion and exclusion criteria for the trial. | (DOCX)Click here for additional data file. | PMC10079055 | ||
Photos of the casts used in the trial. | (DOCX)Click here for additional data file. | PMC10079055 | ||
Baseline data of patients included in the final analysis. | (XLSX)Click here for additional data file. | PMC10079055 | ||
Initial trial protocol. | (DOC)Click here for additional data file.Lauri Raittio, M.D., Joni Hirsimäki, M.D. | PMC10079055 | ||
References | PMC10079055 | |||
Subject terms | microalbuminuria, diabetic nephropathy | BLOOD, DIABETIC NEPHROPATHY | The aim of the present study was to investigate the effect of linagliptin on microalbuminuria in patients with diabetic nephropathy (DN). The present double-blind randomized placebo-controlled clinical trial was performed on 92 patients with DN who were divided into two groups. The intervention and control groups recei... | PMC9975829 |
Introduction | T2D, diabetic nephropathy, microalbuminuria, Diabetes | METABOLIC DISEASES, DIABETIC NEPHROPATHY, DIABETES | Diabetes is one of the most common metabolic diseases, and its prevalence is increasing in adults, especially in developing countries such as IranTherefore, considering the limited and contradictory clinical evidence reporting the therapeutic effects of DPP-4 inhibitors, especially linagliptin, on diabetic nephropathy ... | PMC9975829 |
Methods | PMC9975829 | |||
Design of the study and participants | T2D, microalbuminuria, nephropathy | MYOCARDIAL INFARCTION, STROKE, COMPLICATIONS, NEPHROPATHY, TRANSIENT ISCHEMIC ATTACK | This double-blind, randomized, placebo-controlled clinical trial was performed on 92 patients with T2D and nephropathy that referred to the Isfahan Endocrine and Metabolism Research Center from November 2019 to April 2021.Inclusion criteria consisted of T2D patients age ≥ 18 years, and microalbuminuria (urine albuminFu... | PMC9975829 |
The process of implementing interventions and measuring research variables | T2D, high-density lipoprotein, hypoglycemic, ’ eating habits, Diabetes, TG, diabetes | DIABETES, COMPLICATIONS, DIABETES | The study was approved by the Isfahan University of Medical Sciences ethics committee (Approval no. IR.MUI.MED.REC.1397.230), and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients. The study protocol was registered at irct.ir as IRCT20171030037093N11 (... | PMC9975829 |
Statistical analysis | The collected data were analyzed by SPSS software (ver.26) (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp.). Quantitative and qualitative variables were reported as means ± standard deviation (SD) and number (percentage), respectively. Kolmogorov–Smirnov test and Q-Q diagram were used to check the normality of ... | PMC9975829 | ||
Ethical approval | All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics Committee of the Is... | PMC9975829 | ||
Informed consent | Written informed consent was obtained from all patients for precipitation and registration. | PMC9975829 | ||
Discussion | hepatic cholestasis, diabetic nephropathy, diabetic, microalbuminuria, diabetic kidney diseases | DIABETIC NEPHROPATHY | Since there were several studies on the effectiveness or ineffectiveness of linagliptin on albumin excretion in urineOn the other hand, FPG and HbA1C had a significant decrease in both linagliptin and control groups. A study, conducted by Ito et al. indicated that the mean level of HbA1C in the two groups with and with... | PMC9975829 |
Acknowledgements | The authors would like to express their special gratitude to Alhavi Pharmaceutical Company for its continued support and cooperation in the present study by providing the linagliptin and placebo tablets. The address of Alhavi Pharmaceutical Company is 12th Kilometer of Karaj Makhsos road, Tehran, IRAN. | PMC9975829 | ||
Author contributions | M.K. and J.A. designed the study, interpreted the data and wrote the manuscript. M.A., and F.M. designed the study and interpreted the data. A.F. contributed to the statistical analysis and interpretation of data. A.A. contributed to conducting the research, interpreting the data and reviewed the manuscript. All author... | PMC9975829 | ||
Funding | This work supported by deputy research and technology of Isfahan University of Medical Sciences (Grant# 397535). | PMC9975829 | ||
Data availability | The data that support the findings of this study are available on request from the corresponding author, A. A. The data are not publicly available due to their containing information that could compromise the privacy of research participants. | PMC9975829 | ||
Competing interests | The authors declare no competing interests. | PMC9975829 | ||
References | PMC9975829 | |||
1. Introduction | respiratory illness, inflammation, reinfection, infections | INFLAMMATION, INFECTIONS, COVID-19 INFECTION, CORONAVIRUS, MAY, REINFECTION, CRITICAL ILLNESS, REGRESSION, BLOOD, INFLAMMATORY DISEASE | COVID-19 infection and vaccination offer disparate levels of defense against reinfection and breakthrough infection. This study was designed to examine the effects of curcumin supplementation, specifically HydroCurc (CURC), versus placebo (CON) on circulating inflammatory biomarkers in adults who had previously been di... | PMC10096702 |
2. Materials and Methods | PMC10096702 | |||
2.1. Participants | word of mouth | MAY, COVID-19 INFECTION | This study was conducted between June 2021 and May 2022. Healthy adults between the ages of 18 and 65 years, who had previously tested positive for COVID-19 as per a positive RT-PCR test, and had subsequently received the full primary series of monovalent vaccine doses were recruited via online advertisements, social m... | PMC10096702 |
2.2. Study Protocol | coin toss | Initially this study was designed to recruit participants who has recently tested positive for COVID-19 (within the prior 10–15 days) and were unvaccinated. However, in December of 2020, the Pfizer-BioNTech COVID-19 vaccine was made available under emergency use authorization by the US Food and Drug Administration (FDA... | PMC10096702 | |
2.3. Dietary Supplementation | Participants assigned to the active treatment group (CURC) ingested 500 mg HydroCurc | PMC10096702 | ||
2.4. Analysis of Blood Samples | BLOOD, ADHESION | At baseline and week 4, participant blood samples were collected from the antecubital vein via standard phlebotomy techniques into appropriate vacutainers. Blood was collected in 4 mL dipotassium EDTA tubes and 8.5 mL serum separator tubes. After centrifugation, a portion of collected serum was aliquoted and stored at ... | PMC10096702 | |
2.5. Statistical Analysis | REGRESSION | Demographic and baseline participant characteristic data are displayed as the mean ± SD or number (%). We aimed to investigate the effects of curcumin supplementation for four weeks on a panel of circulating cytokines compared to the placebo. Initially, we examined histograms of cytokine concentrations and applied log ... | PMC10096702 | |
3. Results | PMC10096702 | |||
3.1. Study Participants and Intervention Compliance | gastrointestinal distress, light-headedness | We received 288 respondents to the initial screening survey. Of the participants screened for eligibility, a total of 36 participants met inclusion criteria and were enrolled in the trial. One participant randomized to the CURC group withdrew prior to the study initiation due to scheduling conflicts, and one participan... | PMC10096702 | |
3.2. Dietary Intakes | Dietary analysis was completed based on structured 24 h dietary recalls performed by a trained study staff member following the multiple pass method at baseline and week 4. Analysis of diet records obtained throughout the trial did not reveal significant differences between the CURC and CON groups based on the change (... | PMC10096702 | ||
3.3. Inflammatory Biomarkers | REGRESSION | We aimed to examine the between group differences in post-trial inflammatory biomarker concentrations adjusting for baseline levels of the outcome and covariates. The results of the linear regression analyses revealed that assignment to the CURC group was associated with significantly lower mean post-trial concentratio... | PMC10096702 | |
4. Discussion | pneumonia, inflammation, ARDS, infection, cold-like | PNEUMONIA, INFLAMMATION, DISEASE, INFECTION, ARDS, ACUTE RESPIRATORY DISTRESS SYNDROME, INFLAMMATORY RESPONSE | In this double-blinded randomized placebo-controlled parallel arm trial, we demonstrated the anti-inflammatory effects of ingesting 500 mg of HydroCurc twice daily on circulating inflammatory biomarkers in adults who had previously tested positive for COVID-19 and were subsequently vaccinated, compared to placebo. Spec... | PMC10096702 |
5. Conclusions | inflammation, COVID-19 infection | INFLAMMATION, COVID-19 INFECTION | This study investigated the anti-inflammatory and prophylactic effects of curcumin in individuals who had recovered from COVID-19 infection and were subsequently vaccinated. We demonstrated that curcumin supplementation was associated with significantly lower levels of the proinflammatory cytokines IL-6 and MCP-1, whic... | PMC10096702 |
Supplementary Materials | The following supporting information can be downloaded at: Click here for additional data file. | PMC10096702 | ||
Author Contributions | C.S.J., Y.C., L.L. and S.N.F., conceptualization; C.S.J., Y.C., L.L. and S.N.F., methodology; C.S.J. and S.N.F., project administration; C.S.J., Y.C., L.L. and S.N.F., supervision; S.N.F., investigation; L.L. and S.N.F., formal analysis; S.N.F. and C.S.J., writing—original draft preparation; C.S.J., Y.C., L.L. and S.N.... | PMC10096702 | ||
Institutional Review Board Statement | The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Arizona State University (STUDY 00012406). | PMC10096702 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10096702 | ||
Data Availability Statement | The data presented in this study are available on request from the corresponding author. | PMC10096702 | ||
Conflicts of Interest | The authors declare no conflict of interest. The sponsors had no role in the execution, interpretation, or writing of the study. | PMC10096702 | ||
Abbreviations | tumor necrosis, COPD | TUMOR NECROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, COPD, ADHESION, DISEASE | CURC: 500 mg HydroCurc twice daily; CON, placebo; hsCRP, high sensitivity C-reactive protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; sICAM-1, soluble intercellular adhesion molecule 1; IFN, interferon; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; NF-κB, nuclear factor-kappa B; N/L, neu... | PMC10096702 |
Subject terms | mentalizing deficits, deficits in mentalizing in, various deficits, psychosis, cognitive deficits, psychotic symptoms, Schizophrenia, schizophrenia, reduced mentalizing performance | SYNDROME, POSITIVE | Schizophrenia is associated with various deficits in social cognition that remain relatively unaltered by antipsychotic treatment. While faulty glutamate signaling has been associated with general cognitive deficits as well as negative symptoms of schizophrenia, no direct link between manipulation of glutamate signalin... | PMC10567921 |
Introduction | deficits in social cognition, psychosis, schizophrenia, cognitive domain | People with schizophrenia frequently show deficits in social cognition, a cognitive domain comprising multiple processes including social cue perception, mentalizing, regulation of emotion and experience sharingWhile in some instances social cognition or mentalizing were shown to improve upon treatment with atypical an... | PMC10567921 | |
Methods | PMC10567921 | |||
Ethical approval | The randomized and placebo-controlled study was performed in accordance with the declaration of Helsinki after being approved by the local ethics committee at the Department of Psychology at the University of Bonn, Germany. Data was collected in an MRI facility at the University Hospital of Bonn between June 2019 and S... | PMC10567921 | ||
General procedure | ADVERSE EVENTS, ADVERSE EFFECTS, SYNDROME, POSITIVE | On the day of the experiment, participants were required to arrive with an empty stomach, having fasted food at least 6 h and clear fluids 2 h prior to examination. Participants gave written informed consent and received written instructions. After medical examination by an anesthesiologist, an intravenous access was a... | PMC10567921 | |
Drug administration | A subanesthetic dose of ketamine was delivered via a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels were 100 ng/ml with an initial bolus administered as a 2 mg/ml solution. The plasm... | PMC10567921 | ||
Experimental task | We employed a modified version of the MASC task, which assesses mentalizing performance using a set of videos depicting subsequent stages of social interactions between four human agents. The four agents spend an evening together, take part in various activities and interact in friendly, hostile, or romantic ways. The ... | PMC10567921 | ||
PANSS | schizophrenia | SYNDROME, POSITIVE | The Positive and Negative Syndrome Scale (PANSS) is a semi-standardized medical interview used for measuring symptom severity in schizophrenia. Symptoms are by default subdivided into positive symptoms, negative symptoms and general symptoms | PMC10567921 |
fMRI image acquisition and data analysis | Images were acquired using a 3T Siemens TrioTim MRI scanner (Siemens, Erlangen, Germany). Because participants wore pneumatic headphones, we used a 12- instead of a 32-channel headcoil as the latter was too small to fit participants’ heads with headphones. Using a 12-channel headcoil does not significantly decrease blo... | PMC10567921 | ||
fMRI data analysis | REGRESSION | For each participant, a fixed-effects general linear model (GLM) was fitted to the preprocessed BOLD signal data using SPM12. The GLM contained separate sets of four regressors for the social and physical trials, modeling the following trial parts: presentation of the question before and after the video, presentation o... | PMC10567921 | |
Analysis of the behavioural data | Behavioural data were analyzed using SPSS 27 (IBM Corp., Armonk, USA). Effects of substance on PANSS were tested using independent samples | PMC10567921 | ||
Results | PMC10567921 | |||
Effects of ketamine on symptoms of schizophrenia | Participants under ketamine showed significantly more schizophrenia-related symptoms than controls in four of the five factors used to assess the PANSS data: positive symptoms ( | PMC10567921 | ||
Effects of ketamine on mentalizing | Participants made more errors in the social than in the physical trials of the modified MASC task (Effects of ketamine on mentalizing: participants under ketamine gave more “no mentalizing” answers in our movie-based theory-of-mind task (modified MASC) than controls; | PMC10567921 | ||
Neural correlates of mentalizing under ketamine | We expected social trials to evoke BOLD signal increases in social brain regions when compared to physical trials (control). This manipulation check was performed on the data of the placebo participant group creating a second-level model, using the SOC > PHY contrast images for the question part of the trial. Results (... | PMC10567921 | ||
Discussion | mentalizing deficits, schizophrenia and deficits in social cognition, schizophrenia, with reduced neurocognitive functioning, social cognitive dysfunction | DISORDER, MRS, CORTEX | The present study indicates that a dose of ketamine inducing positive and negative symptoms associated with schizophrenia impairs mentalizing during the observation of social interactions and increases neural activity in right pSTS as well as connectivity between right pSTS and anterior precuneus during this task. Thes... | PMC10567921 |
Limitations | schizophrenia, neurocognitive and social cognitive deficits, psychosis | DISORDERS, MRS | Limitations in our study concern the behavioral task, the ketamine-model for psychosis and whether changes evoked by ketamine reflect changes in glutamate-signalling. In our task, participants relied both on visual and acoustic features of the video clips to perform the social task, while solely visual information matt... | PMC10567921 |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-44443-6. | PMC10567921 | ||
Acknowledgements | The authors would like to thank Laura Augsburg and Lisanne vom Schemm for assistance in data collection, Paul Jung for assistance in experiment programming and Isabel Dziobek for kindly allowing use and adaptation of the MASC task. | PMC10567921 | ||
Author contributions | S.W.: conceptualization, resources, data curation, software, formal analysis, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing; J.S.: conceptualization, resources, data curation, software, formal analysis, supervision, validation, visualiz... | PMC10567921 | ||
Funding | Open Access funding enabled and organized by Projekt DEAL. SW was partially funded by BMBF project ESPRIT (EUDRA-CT: 2014-003076-22). Open access funding provided by University of Bonn. | PMC10567921 | ||
Competing interests | The authors declare no competing interests. | PMC10567921 | ||
References | PMC10567921 | |||
1. Introduction | weight gain, depression, Sedentary behavior | PRETERM BIRTH, GESTATIONAL DIABETES MELLITUS, SECONDARY, DELIVERY COMPLICATION, PREECLAMPSIA | Pregnancy is often associated with poor sleep and high sedentary time (SED). We investigated the effect of physical activity (PA) interventions on sleep and SED in pregnant women. A secondary analysis of a randomized controlled trial (Pregnant women benefit from physical activity (PA) during pregnancy, including a decr... | PMC10094525 |
2. Methods | PMC10094525 | |||
2.1. Ethics and Public Involvement | The FitMum study was approved by the Danish National Committee on Health Research Ethics (#H-18011067) and the Danish Data Protection Agency (#P-2019-512). The study adheres to the principles of the Helsinki declaration and is registered at | PMC10094525 | ||
2.2. Setting | MAY | This study was conducted at the Department of Gynaecology and Obstetrics at the public hospital Copenhagen University Hospital—North Zealand, Hillerød. Participation in the FitMum RCT was free of charge. The first participant was included in October 2018, and the last participant gave birth in May 2021. | PMC10094525 | |
2.3. Participants and Study Design | intrauterine pregnancy | Two hundred twenty healthy pregnant women were included. Inclusion criteria were obtaining written informed consent, being 18 years or older, having a maximum gestational age (GA) of 15 weeks, having an ultrasonic-confirmed viable intrauterine pregnancy, having a body mass index of 18.5–45 kg/m | PMC10094525 | |
2.4. Interventions | The aims and primary results of the FitMum study have been published elsewhere [ | PMC10094525 | ||
2.5. Outcomes | PMC10094525 | |||
2.5.1. Sleep Quantity and Quality by Pittsburgh Sleep Quality Index | The Danish version of the self-administered Pittsburgh Sleep Quality Index (PSQI) questionnaire [ | PMC10094525 | ||
2.5.2. Sedentary Time by the Pregnancy Physical Activity Questionnaire | The Pregnancy Physical Activity Questionnaire (PPAQ) was designed and developed to determine PA intensity and duration during pregnancy [ | PMC10094525 | ||
2.5.3. Sleep and Sedentary Time by the Activity Tracker | The activity tracker data management and measurement details are published elsewhere [Moreover, the activity tracker shows PA daily values in a detailed log (Epoch log). From the Epoch log, a categorization of time is sorted into sedentary, active, or highly active by algorithms in the activity tracker. Sedentary is de... | PMC10094525 | ||
2.6. Statistical Analysis | For the PSQI and PPAQ outcomes, a constrained linear mixed model was fitted with the observation times as a factor [ | PMC10094525 | ||
3. Results | PMC10094525 | |||
3.1. Participant Characteristics | 219 women were randomised to CON ( | PMC10094525 | ||
3.2. Sleep Quantity and Quality by the Pittsburgh Sleep Quality Index | PSQI was completed by 219 (100%), 180 (82%), and 165 (75%) participants at baseline, GA week 28, and GA week 34, respectively. The mean global PSQI score (6.4 ± 1.9) was above 5 for all three groups at baseline. When comparing the two intervention groups with CON, EXE scored lower (i.e., lower means better) in the glob... | PMC10094525 | ||
3.3. Sedentary Time by the Pregnancy Physical Activity Questionnaire | At GA week 28, SED (h/day) from PPAQ was lower for EXE compared to both CON (−0.69 [−1; −0.0], Additionally, average SED (h/day) decreased among all participants (time effect) from baseline to GA week 34 (−1.1 [−1.5; −0.67], | PMC10094525 | ||
3.4. Sleep and Sedentary Time by the Activity Tracker | The unadjusted average of sleep time (h/day) for all participants was (8.2 [8.1; 8.3]), (8.0 [7.9; 8.1]) and (7.8 [7.8; 7.9]), respectively, at GA week 28, GA week 34 and delivery. Moreover, the unadjusted average SED (h/day) for all participants was (13.1 [12.9; 13.2]), (13.2 [13.0; 13.3]) and (13.5 [13.2; 13.6]), res... | PMC10094525 | ||
3.5. COVID-19 Impact on Sleep and Sedentary Time as Measured by the Activity Tracker | No overall differences in sleep time and SED from randomization to delivery were found between participants ending the intervention before the COVID-19 pandemic (physical intervention only, | PMC10094525 | ||
3.6. Comparison of Sleep Time from the Activity Tracker and the Pittsburgh Sleep Quality Index | We compared sleep time from the activity tracker and PSQI. At baseline, GA week 28, and GA week 34, the correlations were weak (r = 0.17, 0.27, and 0.31 ( | PMC10094525 | ||
4. Discussion | SECONDARY | In this secondary analysis of the FitMum RCT, we found that the overall sleep quality, as determined by PSQI, was better in EXE than CON at GA week 28 and better in both EXE and MOT than CON at GA week 34. Moreover, EXE had less SED than MOT and CON at GA week 28, according to PPAQ. The activity tracker showed no signi... | PMC10094525 | |
4.1. Effectiveness of Physical Activity Interventions on Sleep Quality as Determined by the Pittsburgh Sleep Quality Index | We observed a relatively high mean global PSQI score at baseline, which is similar to other findings among pregnant women [ | PMC10094525 | ||
4.2. Effectiveness of Physical Activity Interventions on Sedentary Time as Determined by the Pregnancy Physical Activity Questionnaire | EARLY PREGNANCY | The PPAQ showed lower SED measured in EXE compared to MOT and CON, which contradicts other findings. A 12-week unsupervised exercise intervention in early pregnancy did not affect SED [ | PMC10094525 | |
4.3. Sleep and Sedentary Time as Determined by the Activity Tracker | Like others, we found that sleep decreases [ | PMC10094525 | ||
4.4. Sedentary Time Measured by the Pregnancy Physical Activity Questionnaire and the Activity Tracker | We observed that SED increased during pregnancy when measured by the activity tracker (approx. 24 min/day) and decreased when measured by PPAQ (approx. 1 h/day). This might be explained by two previous findings from the FitMum study. First, in a validation study, we found a significant underestimation of SED by PPAQ co... | PMC10094525 | ||
4.5. Validity of Activity Trackers for Measuring Total Sleep Time | The validity of the Garmin Vivosport in measuring sleep during pregnancy has not been tested before. One study reviewed the validity of Garmin activity trackers, not including Garmin Vivosport, in measuring sleep and found that sleep time was overestimated by the activity trackers when using a sleep diary as a criterio... | PMC10094525 | ||
4.6. Strengths and Limitations | PA, sleep and SED during pregnancy are difficult to evaluate accurately. It is a strength that this study utilized both reported and device-based methods at different times during pregnancy. The activity tracker was advantageous to continuously capturing sleep time and SED throughout pregnancy. However, the consumer ac... | PMC10094525 | ||
5. Conclusions | This study affirmed that pregnant women are prone to low sleep quality and high SED, which worsens as pregnancy progresses. Pregnant women who received structured supervised exercise training had better sleep quality and less SED than pregnant women receiving standard prenatal care when self-reported. When measured by ... | PMC10094525 | ||
Author Contributions | B.S. initiated and directed FitMum. S.A.A., S.d.P.K., C.B.R., J.M.B., T.D.C., S.M., E.L. and B.S. developed the study protocol. S.d.P.K. and C.B.R. conducted intervention activities and collected data assisted by S.A.A., research assistants, and master students. E.L. was the clinical trial manager and supervised the cl... | PMC10094525 | ||
Institutional Review Board Statement | The FitMum study was approved by the Danish National Committee on Health Research Ethics (#H-18011067) and the Danish Data Protection Agency (#P-2019-512). The study adheres to the principles of the Helsinki declaration and is registered at | PMC10094525 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10094525 | ||
Data Availability Statement | Due to confidentiality, the datasets utilized in the current work are not publicly accessible. However, data are available upon justifiable request from the corresponding author, obtained the Danish Data Protection Authority’s consent per the Data Protection Act, and finished a Standard Contractual Clause to ensure the... | PMC10094525 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.